These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Yang CY; Lin MW; Chang YL; Wu CT; Yang PC Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614 [TBL] [Abstract][Full Text] [Related]
23. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673 [TBL] [Abstract][Full Text] [Related]
24. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients. Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020 [TBL] [Abstract][Full Text] [Related]
25. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826 [TBL] [Abstract][Full Text] [Related]
26. NME4 suppresses NFκB2-CCL5 axis, restricting CD8+ T cell tumour infiltration in oesophageal squamous cell carcinoma. Zheng S; He S; Liang Y; Liu Q; Liu T; Tan Y; Peng T; Huang C; Gao H; Lu X Immunology; 2024 Oct; 173(2):408-421. PubMed ID: 39016535 [TBL] [Abstract][Full Text] [Related]
27. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma. Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580 [TBL] [Abstract][Full Text] [Related]
28. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Baba Y; Nomoto D; Okadome K; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H Cancer Sci; 2020 Sep; 111(9):3132-3141. PubMed ID: 32579769 [TBL] [Abstract][Full Text] [Related]
29. Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. Kuriyama K; Higuchi T; Yokobori T; Saito H; Yoshida T; Hara K; Suzuki S; Sakai M; Sohda M; Higuchi T; Tsushima Y; Asao T; Kaira K; Kuwano H; Shirabe K; Saeki H Cancer Sci; 2020 Jun; 111(6):1969-1978. PubMed ID: 32302443 [TBL] [Abstract][Full Text] [Related]
31. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. Chen MF; Chen PT; Chen WC; Lu MS; Lin PY; Lee KD Oncotarget; 2016 Feb; 7(7):7913-24. PubMed ID: 26761210 [TBL] [Abstract][Full Text] [Related]
32. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma. Wu X; Ke X; Ni Y; Kuang L; Zhang F; Lin Y; Lin W; Xiong X; Huang H; Lin X; Zhang H J Immunol Res; 2020; 2020():8884683. PubMed ID: 33457428 [TBL] [Abstract][Full Text] [Related]
33. Clonal distribution and intratumour heterogeneity of the B-cell repertoire in oesophageal squamous cell carcinoma. Zhang C; Huang H; Miao Y; Xiong H; Lu Z J Pathol; 2018 Nov; 246(3):323-330. PubMed ID: 30027584 [TBL] [Abstract][Full Text] [Related]
34. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer. Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036 [TBL] [Abstract][Full Text] [Related]
35. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072 [TBL] [Abstract][Full Text] [Related]
36. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523 [TBL] [Abstract][Full Text] [Related]
37. Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma. Zhao S; Hu X; Zhou P; Li A; Chen L; Wang D; He J; Jiang Y Cancer Biol Ther; 2023 Dec; 24(1):2256927. PubMed ID: 38032149 [TBL] [Abstract][Full Text] [Related]
38. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4 Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422 [TBL] [Abstract][Full Text] [Related]
39. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124 [TBL] [Abstract][Full Text] [Related]
40. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]